U.S. markets closed

Astellas Pharma Inc. (ALPMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.30+0.03 (+0.23%)
At close: 3:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.26
Open15.24
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.21 - 15.33
52 Week Range13.41 - 18.43
Volume84,898
Avg. Volume67,438
Market Cap28.265B
Beta (5Y Monthly)0.61
PE Ratio (TTM)25.84
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.39 (2.54%)
Ex-Dividend DateSep 28, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
    Benzinga

    Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics

    Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associated with muscle weakness. Astellas had extended the research pact initially set to expire on December 31 last year, through March of this year. But last week, Astellas gave written notice that it wants out of the pact altogether and gives up “all licenses and other rights” granted through the pact. In 2013, Astellas had initially signed up to get exclusive rights to co-develop and sell skeletal sarcomere activators in all indications. In turn, Cytokinetics had the right to co-promote and do some sales work in the U.S., Canada, and Europe. Should these drugs have been taken forward solely by Astellas, Cytokinetics could have received over $450 million in pre-commercialization and commercialization milestones plus royalties. No reason was given for the breakup, which will be official this November 1, nor updates on the programs. Cytokinetics is set to release its financials later this week. It comes two years after Cytokinetics’ reldesemtiv missed the primary endpoint in phase 2 amyotrophic lateral sclerosis trial. The Astellas-partnered drug failed to beat placebo on a lung function test in May 2019. It also comes a few months after Amgen Inc (NASDAQ: AMGN) culled its pact with Cytokinetics for heart failure omecamtiv mecarbil after unimpressive Phase 3 data. Price Action: CYTK shares are up 1.65% at $25.86, and ALPMY shares are up 0.98% at $15.14 during market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaBristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs SalesAmgen Shares Drop On Light First Quarter Earnings Hit By Lower Prices© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold
    Benzinga

    Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold

    In a financial notice posted earlier today, Astellas Pharma Inc (OTCMKTS: ALPMY) said it was taking an impairment loss of ¥58.8 billion ($540 million) because of last year’s FDA clinical hold on Audentes’ AT132, gene therapy X-linked myotubular myopathy (XLMTM), a rare muscle-wasting disorder that is usually evident at birth. Last year, Audentes told patient groups that an XLMTM patient had died after receiving AT132. The patient, one of the three older children who received a higher dose in the trial, died from sepsis. The trial enrolled patients up to 5 years of age. Then again, Audentes shared details of a second death: The patient was another one of the three older children treated with the trial’s higher dose. The second patient who died suffered from progressive liver disease in the four to six weeks after AT132 therapy. Things then got worse after a third patient died in August, with early data suggesting the “immediate cause of death was gastrointestinal bleeding.” The child was the last of the three older trial participants who received the higher dose. At the end of the year, Audentes won a reprieve when the FDA lifted the hold to continue with the trial but with a lower dose. The company added: “There is no change to our plan to continue development. We will conduct future discussions with regulators on the path forward toward registration filings for AT132.” Astellas completed the $3 billion Audentes Therapeutics buyout last year. Price Action: ALPMY shares are down 3% at $14.73 during market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaEli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease IndicationsSorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
    Zacks

    Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review

    The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.